MCF Advisors’s Novavax NVAX Stock Holding History

MCF Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10	Closed	-$1K	–	857
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	718
2022 Q1	$1K	Buy	+10	New	+$892	﹤0.01%	724
2021 Q3	–	Sell	-15	Closed	-$3K	–	790
2021 Q2	$3K	Buy	+15	New	+$2.75K	﹤0.01%	512

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCF Advisors's NVAX Position: Q3 2022 in Review

MCF Advisors sold out of Novavax (NVAX) in Q3 2022, closing a stake of 10 shares — an estimated $1K sold.

MCF Advisors first reported a position in NVAX in Q2 2021 and held it in 3 quarters. The position peaked at $3K in Q2 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

MCF Advisors reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
MCF Advisors sold 10 Novavax shares in Q3 2022, an estimated $1K.
MCF Advisors first reported a position in Novavax in Q2 2021 and held it in 3 quarters.
MCF Advisors's Novavax position peaked at $3K in Q2 2021.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on MCF Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.